Navigation Links
Therapix Biosciences to Ring the Nasdaq Stock Market Opening Bell on June 28
Date:6/27/2017

TEL AVIV, Israel, June 27, 2017 /PRNewswire/ -- Therapix Biosciences Ltd. (Nasdaq: TRPX) ("Therapix"), a specialty clinical-stage pharmaceutical company specializing in the development of cannabinoid-based drugs, today announced that the Company will ring The Nasdaq Stock Market Opening Bell in New York, NY on Wednesday, June 28, 2017 in honor of its initial public offering (IPO) of American Depository Shares (ADSs) listed on the Nasdaq Capital Market in March 2017.

Dr. Elran Haber, Ph.D., Chief Executive Officer of Therapix, stated, "We're proud to celebrate the successful uplisting to the Nasdaq Capital Market as Therapix builds recognition in the U.S. markets to grow exposure to a broader and more diverse investor audience. As we ring the opening bell, I would also like to take this moment to acknowledge and thank the employees, investors and partners who have supported Therapix in our journey thus far. With Therapix running two U.S. clinical studies in 2017 and data on one of them to be released this year, today's celebration comes at a landmark point in our timeline."

A live webcast of The Nasdaq Stock Market Opening Bell ceremony will be available at https://livestream.com/nasdaq/live and also on the Investor Relations portion of Therapix's website at www.therapixbio.com.

Therapix began trading on the Nasdaq Capital Market on March 22, 2017, under the symbol "TRPX".

About Therapix Biosciences

Therapix Biosciences Ltd. (Nasdaq: TRPX) is a specialty clinical-stage pharmaceutical company focused on developing technologies and therapeutics based on cannabinoid pharmaceuticals. The Company's clinical pipeline assets follow a de-risked 505(b)(2) regulatory pathway benefitting from Therapix's unique proprietary formulations based on repurposing an FDA approved synthetic cannabinoid (dronabinol). Therapix's lead compound, THX-TS01, is currently in Phase 2 clinical trials for Tourette's Syndrome and the Company intends to initiate a Phase 1 clinical study of THX-ULD01 for the treatment of Mild Cognitive Impairment, for which no FDA-approved therapies currently exist. Please visit our website for more information at www.therapixbio.com.

Contacts

Josh Blacher
Chief Financial Officer
josh@therapixbio.com

Tirth Patel (investors)
Edison Group
tpatel@edisongroup.com


To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/therapix-biosciences-to-ring-the-nasdaq-stock-market-opening-bell-on-june-28-300480633.html


'/>"/>
SOURCE Therapix Biosciences Ltd
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. Therapix Biosciences to Present at Upcoming Scientific and Investor Conferences in June
2. Therapix Biosciences Ltd. Announces Full Exercise of Underwriters Over-Allotment Option
3. Therapix Biosciences Ltd. Announces Closing of U.S. Initial Public Offering of American Depositary Shares; 2,000,000 American Depository Shares Priced at $6.00 per ADS
4. Therapix Biosciences Ltd. Announces Pricing of U.S. Initial Public Offering and NASDAQ Listing
5. Therapix Biosciences Provides Portfolio Update
6. The Israeli Pharma Company Therapix, is Joined by Five Internationally Renowned Experts, From Israel and the World, in the Field of Psychiatry and Tourette
7. 3-V Biosciences to Present Data at the AACR 2017 Annual Meeting in Washington, DC
8. Avelas Biosciences to Present at Needham & Company 16th Annual Healthcare Conference
9. Pressure BioSciences, Inc. Discusses Research Market, Goals and Milestones for First Half of 2017 in New SNNLive Video Interview with StockNewsNow.com
10. Neurocrine Biosciences Announces Conference Call and Webcast to Report Fourth Quarter and Year-End 2016 Results
11. How These Generic Drugs Stocks are Faring? -- Neurocrine Biosciences, Evoke Pharma, SCYNEXIS, and Eagle Pharma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/4/2017)... , Oct. 4, 2017  South Korean-based healthcare product ... training aide "cprCUBE" on Kickstarter. The device will educate ... cardiac arrests with better efficiency compared to the dated ... real-time feedback on efficacy of the compression for a ... has a goal to raise $5,000. ...
(Date:10/4/2017)... , Oct. 4, 2017 OBP ... self-contained, illuminating medical devices, today announced regulatory approval ... Surveillance Agency (or Agência Nacional de Vigilância Sanitária ... single-use, cordless surgical retractor with integrated LED light ... access, illumination and exposure of a tissue pocket ...
(Date:10/2/2017)... 2017  Eli Lilly and Company (NYSE: ... third quarter of 2017 on Tuesday, October 24, 2017. ... day with the investment community and media to further ... call will begin at 9 a.m. Eastern time. Investors, ... webcast of the conference call through a link that ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... ... “America On The Brink”: the Christian history of the United States and the loss ... author, William Nowers. Captain Nowers and his wife, Millie, have six children, ten ... the Navy. Following his career as a naval aviator and carrier pilot, he ...
(Date:10/12/2017)... Francisco, CA (PRWEB) , ... October 12, 2017 ... ... Dr. Cheng, are now treating sleep apnea using cutting-edge Oventus O2Vent ... apnea, a serious sleep disorder characterized by frequent cessation in breathing. Oral appliances ...
(Date:10/12/2017)... WAUSAU, Wis. (PRWEB) , ... October 12, 2017 ... ... formulated standard products to meet the demand of today’s consumer and regulatory authorities ... team of probiotic experts and tested to meet the highest standard. , ...
(Date:10/12/2017)... ... October 12, 2017 , ... The American College of Medical Informatics (ACMI) will ... during the Opening Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual ... F. Collen, a pioneer in the field of medical informatics, this prestigious award is ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the ... to develop to enable prevention of a major side effect of chemotherapy in ... in pediatric patients. For cisplatin, hearing loss is FDA listed on-label as a ...
Breaking Medicine News(10 mins):